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teinuric, further lowering renal NO availability. All of theseProteinuria is preceded by decreased nitric oxide synthesis and
changes can be prevented by a NO donor.prevented by a NO donor in cholesterol-fed rats.
Background. Hypercholesterolemia decreases nitric oxide Alterations in lipid metabolism may be important in
(NO) availability in the circulation and induces podocyte acti- the pathogenesis of progressive renal injury [1]. Short-
vation and renal injury in rats. It is unknown whether hypercho- term high-dose cholesterol feeding causes lipoproteinlesterolemia decreases renal NO availability. To dissociate the
accumulation, monocyte recruitment, and release ofinjury-independent effect of hypercholesterolemia on renal NO
growth factors [2]. It is well known that hypercholesterol-availability from secondary effects of proteinuria, increasing
concentrations of cholesterol were administered. To determine emia induces proteinuria, interstitial injury [3], and oxi-
whether podocyte activation and renal injury were associated dative stress [4]. Such oxidative stress may impair renal
with NO deficiency, molsidomine, an exogenous NO donor, function by decreasing renal nitric oxide (NO) availabil-was administered to hypercholesterolemic rats.
ity [5]. Indeed, in isolated perfused kidneys of rats ex-Methods. Female rats were fed 0, 0.5, 1, or 2% cholesterol
posed to dietary hypercholesterolemia, decreased relax-for 24 weeks. Rats fed 2% cholesterol were also studied for
two weeks. In addition rats fed 0 or 1% cholesterol received ation to acetylcholine was found, indicating a decreased
120 mg molsidomine/L drinking water. Renal NO availability renal NO availability [6]. Similar defects in vascular func-
was determined by measuring renal NO synthesis and superox- tion were found in the renal circulation [7] and renalide activity. Podocyte activation was monitored by desmin
artery segments [8] from hypercholesterolemic pigs. Re-staining.
nal NO availability can be decreased either by decreasedResults. Hypercholesterolemia dose-dependently increased
proteinuria. In the absence of proteinuria, hypercholesterol- NO synthesis or by increased NO degradation. Studies
emia decreased renal NO synthesis (4.2  0.5 in 0.5% choles- in cultured endothelial cells have shown that exposure
terol vs. 6.8  0.6 pmol/min/mg protein in controls; P  0.05). to high cholesterol levels decreased endothelial NO syn-With the exception of neuronal nitric oxide synthase (nNOS),
thase (eNOS) expression [9]. Another study suggestedrenal NOS protein mass remained unaffected. Renal superox-
that in endothelial cells exposed to serum from hyper-ide activity was dose-dependently increased, thus further low-
ering renal NO availability. Podocyte injury was dose-depen- cholesterolemic patients, caveolin-1 expression was up-
dently increased even in the absence of proteinuria (score, 40 regulated and thus inhibited eNOS activity [10]. Thus,
4 in 0.5% cholesterol vs. 9  4 in controls; P  0.05). After endothelial cells exposed to high cholesterol levels ap-two weeks, hypercholesterolemia caused no proteinuria, but
pear to have impaired eNOS activity, which leads todid cause some podocyte injury. Renal NOS activity was de-
decreased endothelial NO availability. The purpose ofcreased, but glomerular endothelial NOS (eNOS) staining was
unchanged. Molsidomine prevented proteinuria, podocyte acti- the present study is to investigate whether hypercholes-
vation, and all further renal injury. terolemia influences renal NOS activity. However, mea-
Conclusions. Hypercholesterolemia decreases renal NO syn- surements in most previous studies in hypercholesterol-thesis, and induces podocyte activation before proteinuria ap-
emic rats were performed when the animals were alsopears. Renal superoxide activity is increased once rats are pro-
proteinuric. In the presence of renal injury it is impossi-
ble to dissociate the effects of hypercholesterolemia from
those of injury. In view of the above results, the presentKey words: hypercholesterolemia, nitric oxide synthase, podocyte, su-
peroxide, molsidomine. study was designed to dissect the primary effect of hyper-
cholesterolemia on renal NO availability from the sec-Received for publication July 13, 2001
ondary effect of injury.and in revised form December 12, 2001
Accepted for publication December 14, 2001 Desmin expression is a marker of podocyte injury [11].
In a previous study we showed that dietary hypercholes- 2002 by the International Society of Nephrology
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terolemia, characterized by marked increases in very Experimental protocol 2: Primary effect
of hypercholesterolemialow-density lipoprotein (VLDL) and intermediate-den-
sity lipoprotein (IDL), was associated with podocyte in- Two groups of rats (N  8/group) were studied for
jury [12]. Podocytes are practically unable to replicate two weeks. The first control group received normal chow
postnatally. Therefore, any injury that podocytes suffer and drinking water. The second group received 2%
might lead to areas of “bare” glomerular basement mem- cholesterol  0.5% cholate in chow. After two weeks,
brane, which are the starting points for irreversible renal plasma cholesterol levels, proteinuria, renal NOS activ-
injury [13]. Podocytes express the NO-dependent en- ity, renal superoxide activity, and podocyte injury were
zyme soluble guanylate cyclase, which probably controls determined.
their contractility [14]. Thus, by decreasing renal NO
Experimental protocol 3: NO availability andavailability, hypercholesterolemia may initiate podocyte
hypercholesterolemia-induced renal injuryinjury.
The present study investigated the injury-independent Two additional groups of rats were studied (N 
effect of dietary cholesterol on renal NO-availability 8/group) for 24 weeks. The first group received the NO
after administration of a non-proteinuric low dose of donor molsidomine in drinking water (120 mg/L). The
dietary cholesterol (0.5%) that would cause dyslipide- drinking bottles were covered with aluminum foil. This
mia. The study further sought to investigate the injury- dose protected uremic rats from developing proteinuria
dependent effect of dietary cholesterol on renal NO and adverse effects were not reported [15]. The second
availability after administration of proteinuric higher group received 1% cholesterol  0.25% cholate in chow
doses of cholesterol in the diet (1% and 2%) that would and molsidomine in drinking water. These groups were
cause mild and severe hypercholesterolemia. Renal NO compared to the control and 1% cholesterol  0.25%
synthase (NOS) activity and renal superoxide activity cholate group from protocol 1.
were measured. Furthermore, we examined whether de- At the end of experimental protocols 1, 2, and 3 the
creased renal NOS activity and podocyte activation oc- right kidney was removed and cut transversely into three
curred before the onset of proteinuria by administering slices. The two poles were frozen in liquid nitrogen and
rats 2% cholesterol for only two weeks. To investigate stored at 80C until being processed for NOS activity
whether renal injury can be prevented by an exogenous and protein mass determination. The middle slice was
NO donor, NO availability was increased with a NO immersion-fixed in phosphate-buffered saline (PBS)
donor (molsidomine [15]) in rats fed 1% cholesterol. formaldehyde (4%, pH 7.35) and embedded in paraffin
for morphological studies. The left kidney was perfused
at 120 mm Hg with ice-cold carbogenized Krebs-HepesMETHODS
buffer (pH 7.4). After perfusion kidneys were decapsu-
Animals lated and four cortical slices were cut (5  5  2 mm)
Female Sprague-Dawley rats (weighing 150 to 175 g; using a tissue-slicing device. Renal cortical slices were
Harlan-Olac, Blackthorn, UK) were exposed to a 12- kept on ice in buffer until determination of superoxide
hour light/dark cycle, an ambient temperature of 22C, activity by lucigenin enhanced chemiluminescence (LEC).
and a humidity of 60%. Sentinel animals were monitored
Plasma lipids, systolic blood pressure, body weight,regularly for infection by nematodes and pathogenic bac-
and renal functionteria as well as for antibodies for a large number of
rodent viral pathogens (International Council for Labo- At weeks 0, 6, and 18, blood samples were taken from
ratory Animal Science, Nijmegen, The Netherlands), and the tail vein for determination of plasma creatinine, cho-
consistently tested negative for infection throughout the lesterol, and triglycerides. At the end of the experiment
experiment. The Utrecht University Board for studies (week 24), the animals were anesthetized with 60 mg/kg
in experimental animals approved the studies. sodium pentobarbital intraperitoneally to collect blood
from the vena cava for determination of plasma creati-
Experimental protocol 1: Dose-dependent effects nine, lipids, and lipoproteins. Plasma cholesterol and
of cholesterol triglycerides were determined enzymatically (Roche Di-
Four groups of rats were studied (N  8/group). Cho- agnostics GmbH, Mannheim, Germany). Systolic blood
lesterol and cholate were mixed through the chow at in- pressure (SBP) was measured every six weeks in the
creasing concentrations (RMH-TM; Hope Farms, Woer- conscious rats, starting one week before the start of treat-
den, The Netherlands): 0% cholesterol  0% cholate; ment (week 0) by the tail-cuff method (IITC, San Diego,
0.5% cholesterol  0.125% cholate; 1% cholesterol  CA, USA). Urine was collected every six weeks starting
0.25% cholate; 2% cholesterol  0.5% cholate. Rats at week 0 for determination of urinary protein and creati-
nine excretion. The rats were weighed and placed inwere treated for 24 weeks starting at the age of six weeks.
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metabolic cages for 24 hours, with free access to food positive controls as well as the peroxidase-conjugated
goat anti-mouse IgG antibody were purchased fromand water. Urinary protein levels were determined by the
Bradford method. Plasma and urinary creatinine levels Transduction Laboratories. Monoclonal actin antibody
was purchased from Sigma. Briefly, 100 g of kidneywere determined colorimetrically (Sigma Diagnostics
Inc., St. Louis, MO, USA). The creatinine clearance, tissue preparations were size-fractionated on 4% to 12%
Tris-Glycine gel (Novex) at 120 V for three hours. Aftercalculated by the standard formula, was used as an esti-
mate of glomerular filtration rate (GFR). electrophoresis, proteins were transferred onto Hybond-
ECL membrane (Amersham Life Science Inc.) at 400
Lipoprotein isolation by density-gradient mA for 120 minutes using the Novex transfer system.
ultracentrifugation The membrane was prehybridized in 10 mL of buffer A
(10 mmol/L Tris hydrochloride, pH 7.5, 100 mmol/LLipoproteins were separated in terminal plasma sam-
ples by density-gradient ultracentrifugation [16] into five NaCl, 0.1% Tween 20, and 10% nonfat milk powder) for
one hour and then hybridized for an additional one-hourfractions [chylomicrons and VLDL, d  1.006 g/mL;
IDL, d  1.006 to 1.019 g/mL; low-density lipoprotein period in the same buffer containing 10 L of the given
NOS antibody (1:1000) or actin antibody (1: 10,000). The(LDL1, d  1.019 to 1.04 g/mL and LDL2, d  1.04 to
1.063 g/mL); high-density lipoprotein (HDL), d  1.063 membrane was then washed for 30 minutes in a shaking
bath, with the wash buffer (buffer A without nonfat milk)to 1.21 g/mL]. The subdivision of LDL into LDL1 and
LDL2 was performed to separate the apolipoprotein B changed every five minutes before one hour of incuba-
tion in buffer A plus goat anti-mouse IgG-horseradish(apo B)-containing lipoproteins from the other particles
present in the total LDL density range of 1.019 to 1.063 peroxidase at the final titer of 1:1000. Experiments were
carried out at room temperature. The washes were re-g/mL. Lipoprotein cholesterol was measured as de-
scribed above. peated before the membrane was developed with a light-
emitting nonradioactive method using an ECL reagent
Renal NOS activity (Amersham Inc.). The membrane was then subjected to
autoluminography for one to five minutes. The autolumi-Nitric oxide synthase activity was measured by de-
termining the formation of l-3H-citrulline from l-3H- nographs were scanned with a laser densitometer (model
PD1211; Molecular Dynamics) to determine the relativearginine. Using an Ultraturrax, an aliquot of about 300
mg kidney tissue was homogenized in an ice-cooled ho- optical densities of the bands. In all instances, the mem-
branes were stained with Ponceau stain before hybridiza-mogenization buffer, pH 7.4, consisting of: 50 mmol/L
Tris buffer, 320 mmol/L sucrose, 1 mmol/L ethylenedi- tion. This step verified the uniformity of protein load
and transfer efficiency across the test samples [18]. Theaminetetraacetic acid (EDTA), 1 mmol/L dithiothreitol
(DTT), 2 mg/L aprotinin, and 100 mg/L phenylmethyl- NOS protein data were normalized against correspond-
ing actin measurements.sulfonyl fluoride (PMSF). An aliquot of 50 L of homog-
enate was incubated in a final volume of 100 L at 37C
Glomerular eNOS immunolocalizationfor 30 minutes in the presence of 1 mmol/L l-citrulline, 0.3
mmol/L tetrahydrobiopterin, 300 U/mL calmodulin, 0.5 Frozen tissue sections (5 m) of rat kidneys from pro-
tocol 2 were fixed in acetone and rinsed twice with PBSTmmol/LNADPH, and 1mmol/LCaCl2,0.01 mmol/Ll-argi-
nine, and 3.7 kbEq l-[2,3,4,5]-arginine (Amersham Phar- (PBS containing 0.05% Tween). Endogenous peroxidase
reactions were blocked with 30% H2O2 in a phosphate-macia Biotech. Ltd, Buckinghamshire, UK) in 50 mmol/L
KH2PO4 phosphate buffer, pH 7.2. In an additional tube, citrate buffer, pH 5.8. Tissue sections were incubated
for one hour at room temperature with eNOS antibodythe NADPH was substituted by 100 mmol/L l-arginine
analog N-nitroso-l-arginine methyl ester (L-NAME) to (1:5000 in 10% PBS; Transduction Laboratories), then
rinsed twice with PBST and fixed with formalin for tendetermine non-specific activity. The reaction was stopped
by placing the tubes on ice and adding 20 mmol/L ice- minutes. Fixed sections were incubated for 30 minutes
at room temperature with rabbit anti-mouse powervisioncold Hepes buffer, pH 5.5, followed by separation of
arginine and citrulline on Dowex 50X8-200 (Na form). (1:100 in PBS with 10% normal rat serum; Dako, Ham-
burg, Germany). After rinsing with PBST, sections were3H-citrulline was detected by scintillation counting. All
measurements were performed in duplicate and the re- incubated for 30 minutes at room temperature with goat
anti-rabbit powervision (Klinipath, Duiven, The Nether-sults are expressed as pmol per min per mg of protein.
lands), rinsed for ten minutes with PBS, then rinsed for
Renal NOS protein mass five minutes with acetate buffer (100 mmol/L, pH 4.8) fol-
lowed by color development in AEC substrate (Sigma)This assay was performed to determine the eNOS,
inducible NOS (iNOS), and neuronal NOS (nNOS) pro- in acetate buffer. After counterstaining with hematoxylin
the sections were covered with paragon. The area stainedtein mass as previously described [17]. Monoclonal anti-
bodies to the three NOS isoforms, and the respective was quantified morphometrically with Optimas software
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(Optimas Corporation, Seattle, Washington, USA) in 20 Immunohistochemistry
glomeruli per kidney at 400 magnification and ex- Immunohistochemistry was carried out on 3 m paraf-
pressed as percentage of the total glomerular area. fin sections of formaldehyde-fixed kidney. Tissue sec-
tions were deparaffinized and dehydrated. Glomerular
Renal superoxide activity desmin staining was used to determine podocyte activa-
Lucigenin enhanced chemiluminescence was mea- tion [11]. Paraffin sections of kidney were stained with
sured using a LUMAT LB 9507 luminometer (Berthold, mu072-uc (Biogenex, San Raman, CA, USA). The outer
Wildbad, Germany) as previously described [19]. Renal cell layer of the glomerular tuft was evaluated. The stain-
cortical slices were pre-incubated for five minutes in 300 ing was scored semiquantitatively by evaluating the per-
centage of the glomerular edge showing positive staining:L buffer (300 mmol/L HEPES, 135.3 mmol/L NaCl,
0  0 to 5% stained; 1  5 to 25%; 2  25 to 50%; 3 4.7 mmol/L KCl, 1.8 mmol/L CaCl2, 1.2 mmol/L MgSO4,
50 to 75%; 4	75%. 50 glomeruli were scored. A total1.2 mmol/L KH2PO4, and 11.1 mmol/L glucose; pH 7.4)
score was determined similarly to the total injury score.in a polystyrene tube in the luminometer at room tem-
Incubation with the ED-1 mouse monoclonal antibodyperature. Then background LEC was measured for two
(kindly provided by Ed Dub, Dept. of Cell Biology, Freeminutes. Aliquots of 300 L of lucigenin (bis-N-methyl
University, Amsterdam, the Netherlands) demonstratedacridinium at a final concentration of 100 mol/L) were
monocytes/macrophages. After application of ED-1 (di-injected and LEC was measured for 18 minutes. Subse-
lution 1:2500 in PBS containing 5% BSA, 0.4% sodiumquently, renal cortical slices were dried overnight and
azide) to the slides at 22C for one hour, bound antibodyweighed. LEC was calculated as the average counts mea-
was detected by the DAKO EnVision System (predi-sured during the last five minutes minus average back-
luted peroxidase-dextran-conjugated goat anti-mouseground counts and expressed as counts per second per
antibody and DAB color reaction). The number of10 mg dry weight. To determine whether LEC was spe-
ED-1–antigen-positive monocyte/macrophage was de-cific for superoxide anion, MnCl2 (2  103 mol/L), a
termined in 50 randomly distributed glomeruli and in 20pH neutral, membrane-permeable compound with su-
microscopic fields with 400 magnification for determi-peroxide dismutase (SOD)-like activity, was added after
nation of monocyte/macrophage infiltration into tubu-measurement of basal O2 activity. Addition of MnCl2
lointerstitium. An average score per glomerulus or percompletely abolished the LEC signal in control as well as
field was calculated.in cholesterol-fed rats, indicating that the signal obtained
with LEC is specific for superoxide. To determine which Statistical analyses
oxidative enzyme might be responsible for superoxide
Results are expressed as mean  SEM. Quantita-production, allopurinol (an inhibitor of xanthine oxidase
tive data were tested by one-way analysis of variance
activity, 1 mmol/L) or diphenyleneiodonium (DPI; an
(ANOVA) in protocol 1 and by two-way ANOVA in
inhibitor of flavin oxidases, 50 mol/L) was added to the
protocol 2. The Kruskal-Wallis ANOVA tested semi-
test tube after basal LEC measurement in renal cortical quantitative data. If the variance ratio (F) reached statis-
slices. The percentage decrease of signal was determined. tical significance (P  0.05), quantitative data were fur-
ther analyzed with the Student-Newman-Keuls test forMorphological studies
multiple comparisons, and semiquantitative data with
Light microscopy was done on 3 m paraffin sections Dunn’s test for multiple comparisons. Data in protocol
of the formaldehyde-fixed kidney stained by hematoxy- 3 were compared by the t test.
lin-eosin. The sections were numbered. The investigators
(D.M.A. Attia and M.A. Attia) were blinded to their
RESULTSidentity. Glomerular injury (aneurysms and glomerular
fibrosis) was assessed in 50 glomeruli with 400magnifi- Protocol 1
cation semi-quantitatively using a 0 to 4 scale: 0 absent, Plasma lipids, systolic blood pressure, body weight, and
1  slight, 2  mild, 3  moderate and 4  marked. renal function. When rats were fed a high cholesterol
Tubulointerstitial damage (tubular dilation, casts, flat- diet, plasma cholesterol levels were dose-dependently
tened tubular epithelium, tubular epithelial cell degener- increased (Fig. 1). There were no differences in plasma
ation/necrosis), tubular cytosolic protein droplets, and triglycerides, SBP, or creatinine clearance between the
peritubular fibrosis were semiquantitatively graded in different groups (data not shown). Rats fed a 2% choles-
twenty fields in the same way as glomerular injury. A terol diet gained significantly more weight during the 24
total glomerular and tubulointerstitial injury score was weeks of treatment than the other groups (148  9 g in
determined by summing (1 score 1) (2 score 2) rats fed 2% cholesterol vs. 115  3 g in the other
groups). However, no tendency to a dose-dependent ef-(3  score 3)  (4  score 4).
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Fig. 2. Proteinuria in control rats () and rats fed 0.5% cholesterolFig. 1. Plasma cholesterol in control rats () and rats fed 0.5% choles-
(), 1% cholesterol (), 2% cholesterol () for 24 weeks. *P  0.05terol (), 1% cholesterol (), 2% cholesterol () for 24 weeks. *P 
versus control; †P  0.05 versus 0.5% cholesterol.0.05 versus control; †P 0.05 versus 0.5% cholesterol; #P 0.05 versus
1% cholesterol.
decrease in nNOS protein mass (0.92  0.05 vs. 0.70 
0.03 NOS/actin ratio in controls; P  0.05; Fig. 4).fect on body weight of chow cholesterol content was
Renal superoxide activity. In rats fed 0.5% cholesterolobserved in the groups on a lower cholesterol intake.
renal superoxide activity was slightly increased after 24The lowest concentration of cholesterol (0.5%) had no
weeks (t test; P  0.05). However in rats fed 1% choles-proteinuric effect during the study period of 24 weeks.
terol renal superoxide was significantly increased andWhen rats were fed 1% cholesterol, proteinuria in-
even more so in rats fed 2% cholesterol (Fig. 3B). Thecreased in week 12 of treatment. Rats fed 2% cholesterol
LEC signal was not decreased by addition of allopurinolalready showed substantial increase in proteinuria at
(1  0.6% decrease of signal), but was significantly de-week 6 of treatment (Fig. 2).
creased after addition of DPI (90.3  2.7% decrease ofLipoprotein isolation by density-gradient ultracentrifu-
signal), indicating that flavin oxidases rather than xan-gation. In all cholesterol-fed animals the observed in-
thine oxidase were responsible for superoxide activitycrease in terminal plasma cholesterol levels was mainly
[17].due to marked dose-dependent increases in VLDL and
Glomerular and tubulointerstitial morphology. By mor-IDL, and to a lesser extent LDL1. However LDL2 levels
phological standards, only rats fed 2% cholesterol devel-were decreased, while HDL levels remained unchanged
oped significant glomerular injury (Table 2 and Fig. 5).(Table 1). Note that this change in distribution also was
Podocyte desmin expression and glomerular monocyte/clearly present in the rats fed 0.5% cholesterol despite
macrophage number were dose-dependently increased inthe lack of increase of terminal plasma total cholesterol
rats fed cholesterol. Rats fed 1% and 2% cholesterol de-concentrations.
veloped tubulointerstitial injury (Fig. 5). The amount ofRenal NOS activity and protein mass. After 24 weeks
protein droplets in tubular epithelial cells and tubulointer-of treatment renal NOS activity was significantly and
stitial monocyte/macrophage number were increased insimilarly decreased at all levels of cholesterol intake,
rats fed 1% and 2% cholesterol, but not in rats fed 0.5%including rats fed only 0.5% cholesterol (Fig. 3A). In
cholesterol (Table 2). There was no difference in peritubu-the latter, renal eNOS and iNOS protein mass were
not significantly decreased, but there was a significant lar fibrosis between these groups (data not shown).
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Table 1. Cholesterol concentrations in lipoprotein fractions in rats fed increasing concentrations of cholesterol
VLDL IDL LDL1 LDL2 HDL
% Cholesterol lmol/L
0 0.040.01 0.130.04 0.180.01 0.660.05 1.950.1
0.5 0.450.08a 0.440.09a 0.250.02 0.190.04a 1.710.2
1 1.530.2ab 1.090.1a 0.480.04ab 0.250.06a 1.720.3
2 2.770.5ab 1.620.6a 0.670.1ab 0.420.05abc 1.490.2
Data are mean  SEM. Abbreviations are: VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein.
aP  0.05 vs. control
bP  0.05 vs. 0.5% cholesterol
cP  0.05 vs. 1% cholesterol
Fig. 3. Renal nitric oxide synthase (NOS) activity (A) and renal superoxide activity (B) in control rats and rats fed 0.5% cholesterol, 1% cholesterol,
or 2% cholesterol for 24 weeks. *P  0.05 versus control; †P  0.05 versus 0.5% cholesterol; #P  0.05 versus 1% cholesterol.
Protocol 2 (3.85  0.67 vs. 4.04  0.83% of glomerular area in
controls; Fig. 6).Rats fed 2% cholesterol for two weeks had increased
plasma cholesterol levels (9.4 0.9 vs. 1.5 0.1 mmol/L
Protocol 3in controls; P  0.05), but did not develop proteinuria
Molsidomine had no effect on body weight, plasma(10  1 vs. 7  1 mg/day in controls). Renal NOS activ-
lipids and lipoproteins, or on creatinine clearance (dataity was significantly decreased (6.3  0.3 vs. 9.1  0.4
not shown). SBP remained unchanged in molsidomine-pmol/min/mg protein in controls; P 0.05). In these rats
treated rats fed normal chow, but was slightly increasedrenal superoxide was unchanged (12  1 vs. 14  2
in 1% cholesterol-fed rats, and this was only significantcounts/sec/10 mg dry wt in controls). Podocyte activa-
at week 18 (data not shown). Administration of molsi-tion was significantly increased (12  2 vs. 5  1 in
domine protected rats fed 1% cholesterol from develop-controls; P  0.05). Glomerular eNOS staining in rats
fed 2% cholesterol was unchanged compared to controls ment of proteinuria (Fig. 7). After 24 weeks of molsido-
Attia et al: Hypercholesterolemia and renal NO1782
Fig. 4. Representative NOS and actin West-
ern blots and data depicting NOS/actin ratio
for neuronal (nNOS), endothelial (eNOS),
and inducible (iNOS) nitric oxide synthases
in kidneys of control rats () and rats fed
0.5% cholesterol ( ) for 24 weeks. *P  0.05
versus control.
Table 2. Glomerular and tubulointerstitial injury in control rats, and rats fed increasing concentrations of cholesterol
Glomerular Podocyte
Glomerular
Interstitial Protein
Interstitialinjury activation
monocytes
injury droplets
monocytes
% Cholesterol score #/glom score #/field
0 2.71.1 94 1.00.1 5.32.1 73 4.50.3
0.5 1.30.7 404a 2.50.2a 4.61.7 52 5.00.5
1 4.30.5 6613a 3.60.2ab 17.53.5ab 152ab 8.50.6ab
2 7.52.1ab 7211ab 8.20.8abc 19.54.6ab 214ab 16.91.7abc
Data are mean  SEM.
aP  0.05 vs. control
bP  0.05 vs. 0.5% cholesterol
cP  0.05 vs. 1% cholesterol
mine administration renal NOS activity was decreased with NO deficiency since it could be prevented by exoge-
nous NO administration.in rats fed normal chow. However, in 1% cholesterol-
Renal NOS activity was decreased before proteinuriafed animals the low renal NOS activity was not decreased
was apparent. Indeed, rats fed 2% cholesterol for twofurther by molsidomine treatment (Fig. 8A). The eleva-
weeks that were not yet proteinuric had decreased renaltion of renal superoxide activity in 1% cholesterol-fed
NOS activity. Long-term hypercholesterolemia decreasedrats was prevented by molsidomine treatment. Molsi-
renal NOS activity even more. However, in rats fed 2%domine alone had no effect on renal superoxide activity
cholesterol for 24 weeks the renal NOS activity was not(Fig. 8B). Combining 1% cholesterol with molsidomine
decreased further compared to rats fed 1% cholesterol,completely prevented renal morphological alterations
possibly due to a marked renal infiltration of monocytes(Table 3). that express high levels of iNOS [20]. Indeed, this was
the group with the highest activity of superoxide in the
kidney. Molsidomine also influenced renal NOS activity.DISCUSSION
It has been described that NO donors depress NOS ex-
In the present study we were able to dissociate the pression and activity. For instance, NO donors induce
primary effects of hypercholesterolemia, which were de- serine phosphorylation of eNOS in endothelial cells,
creased renal NOS activity and podocyte injury, from thereby inhibiting its activity [21]. Nitroprusside, a NO
the secondary effects of proteinuria, which were tubulo- donor, decreased eNOS expression in aorta via a cGMP-
interstitial monocyte influx, renal superoxide activity, mediated mechanism [22]. To our knowledge, this is the
and interstitial injury. Furthermore, hypercholesterol- first study to demonstrate such an inhibitory effect of a
NO donor on NOS in the kidney.emia-induced podocyte injury seemed to be associated
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Fig. 5. Representative light microscopic features of renal morphological changes in rats fed 0, 0.5, 1, and 2% cholesterol for 24 weeks. (A) Normal
glomerulus and tubulointerstitium in rats fed 0% cholesterol. (B) Rats fed 0.5% cholesterol had no glomerular or tubulointerstitial injury. (C)
Rats fed 1% cholesterol showed protein casts, flattened tubular epithelium, tubular basophilia, and slight glomerular ischemia. (D) Rats fed 2%
cholesterol showed more extensive tubulointerstitial damage, as well as glomerular damage including focal adhesions to Bowman’s capsule.
crease renal eNOS or iNOS protein mass. On the other
hand, nNOS protein mass was decreased. A recent study
showed that both eNOS and nNOS isoforms are abun-
dantly expressed in the renal vasculature [23]. The role
of nNOS in the renal vasculature is unknown. Although
it appears that hypercholesterolemia inhibited renal
NOS activity, the present study does not allow us to
conclude through which pathway hypercholesterolemia
inhibits renal NOS activity. However, previous studies
have demonstrated that hypercholesterolemia might im-
pair tetrahydrobiopterin bioavailability, an important
cofactor of NOS [24]. In patients with familial hypercho-
Fig. 6. Representative light microscopic features of glomerular eNOS lesterolemia forearm blood flow improved after tetrahy-immunohistochemistry. Rats fed 2% cholesterol for two weeks showed
no difference in staining compared to control rats (3.85  0.67% vs. drobiopterin infusion [25]. In that case NOS becomes a
4.04  0.83%). superoxide instead of a NO producing enzyme. How-
ever, in the present study, both rats fed 0.5% cholesterol
for 24 weeks and rats fed 2% cholesterol for two weeks
had decreased renal NOS activity but no increased renalSeveral mechanisms could play a role in the reduction
superoxide activity. Thus, it seems that in this modelof renal NOS activity associated with hypercholesterol-
NOS does not become a superoxide producing enzyme.emia. It has been proposed that hypercholesterolemia
Alternatively, NOS might bind to the inhibitory proteindecreases eNOS expression in endothelial cells [9]. How-
caveolin. In endothelial cells exposed to hypercholester-ever, in the present study mild hypercholesterolemia,
which did decrease NOS activity, did not seem to de- olemic serum, caveolin-1 expression was up-regulated
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cultured endothelial cells where hypercholesterolemia
increased superoxide production in parallel with de-
creased NO production [29]. However, unlike isolated
endothelial cells in culture, the intact kidney contains
additional powerful scavenging systems, such as hemo-
globin. Superoxide activity may only become apparent
when its production overwhelms these scavenger sys-
tems. In the present study, we found increased cytosolic
protein droplets in tubular epithelial cells and tubuloin-
terstitial infiltration of macrophages in the presence of
proteinuria. Indeed, tubular reabsorption of leaking pro-
teins increases tubulointerstitial macrophage influx [30].
Both macrophages [31] and renal epithelial cells [32, 33]
are potential sources of superoxide production in the
kidney. In the female rats used in the present study,
renal superoxide production was only increased when
proteinuria increased fourfold, and when tubulointersti-
tial injury and monocyte influx became apparent. Once
renal NOS activity is already decreased, superoxide
anions may cause a further decrease in renal NO-avail-
ability due to peroxynitrite formation [5]. It has been
shown in severely proteinuric nephrotic rats that admin-
istration of molsidomine worsened cortical lipid peroxi-
dation and injury [34]. This suggests that when renal
Fig. 7. Proteinuria in control rats (), in rats receiving molsidomine superoxide activity is increased, exogenous NO can in-
in drinking water (), in rats fed 1% cholesterol (), and in rats fed crease peroxynitrite production. Hence, NO donors such
1% cholesterol and receiving molsidomine in drinking water (), for
as molsidomine may only be useful to ascertain primary24 weeks. *P  0.05 versus control; #P  0.05 versus 1% cholesterol.
renal NO deficiency, that is, to supplement NO before
the onset of severe renal injury.
Desmin expression is a marker of podocyte injury [11].
[10]. Caveolin binds to NOS thereby inhibiting its NO In a previous study we showed that dietary hypercholes-
synthesizing capacity. More calmodulin binding is re- terolemia, characterized by marked increases in VLDL
quired to reactivate the enzyme [10]. Another possibility and IDL [35, 36], was associated with podocyte injury
is that hypercholesterolemia increases levels of an endoge- [12]. However, in that study increased desmin expression
nous NOS inhibitor, asymmetrical dimethyl l-arginine coincided with increased proteinuria [12]. In the present
(ADMA) [26]. Short-term dietary exposure to 4% cho- study desmin expression was increased in rats that had no
lesterol causing severe hypercholesterolemia increased proteinuria, or that had not yet developed proteinuria.
renal NADPH diaphorase activity in rats [27]. However Podocytes express LDL receptors and show deposition
another short-term study using the model showed in- of apolipoproteins B and E in glomeruli of patients with
creased renal macrophage influx [28]. This may explain kidney diseases [37], which is in accordance with our
the increase in NADPH diaphorase activity in this model finding that VLDL and IDL were increased after choles-
[27]. However, the somewhat milder hypercholesterol- terol feeding. Furthermore, cultured glomerular epithe-
emia that we studied appeared to decrease renal NOS lial cells bind and take up VLDL [38] and IDL [39].
activity, despite practically normal NOS protein mass, Besides lipoprotein receptors, podocytes also express
thereby lowering renal NO-availability. the NO-dependent enzyme soluble guanylate cyclase,
Renal superoxide activity was only significantly in- although they do not express any isoform of NOS [14].
creased in rats with significant proteinuria, tubulointer- It also has been demonstrated that administration of NO
stitial monocyte influx, and tubulointerstitial injury. to cultured podocytes increased production of cGMP,
Thus, increased superoxide activity seemed to be second- which controls the cytoskeletal structure of the podocyte
ary to proteinuria. Indeed, rats receiving 1% cholesterol and thus limits retraction [40]. Although we did not find
plus molsidomine did not develop proteinuria and had a decrease in glomerular eNOS staining, whole kidney
no increased renal superoxide activity, whereas rats fed NOS activity was decreased and molsidomine could pre-
1% cholesterol alone did. Furthermore, rats fed 2% cho- vent podocyte injury. Thus, hypercholesterolemia ap-
lesterol for two weeks had neither proteinuria nor in- pears to decrease renal NO-availability by stimulating
endogenous inhibitors. Podocytes might be tonically sub-creased renal superoxide activity, which is in contrast to
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Fig. 8. Renal NOS activity (A) and renal superoxide activity (B) in control rats, in rats receiving molsidomine in drinking water, in rats fed 1%
cholesterol, and in rats fed 1% cholesterol and receiving molsidomine in drinking water for 24 weeks. *P  0.05 versus control; #P  0.05 versus
1% cholesterol.
Table 3. Glomerular and tubulointerstitial injury in control rats, rats treated with molsidomine, 1% cholesterol, or cholesterol
in combination with molsidomine
Glomerular Podocyte
Glomerular
Interstitial Protein
Interstitialinjury activation
monocytes
injury droplets
monocytes
Groups score #/glom score #/field
Control 2.71.1 94 1.00.1 5.32.1 73 4.50.3
Molsidomine 0.50.3 184 0.50.1 3.82.6 32 3.20.3
1% Cholesterol 4.30.5 6613a 3.60.2a 17.53.5a 152a 8.50.6a
1% Cholesterol  molsidomine 1.10.6b 165b 0.80.2b 5.81.6b 32b 2.50.6b
Data are mean  SEM.
aP  0.05 vs. control
bP  0.05 vs. 1% cholesterol
jected to oxygen radicals as they contain the superoxide- to be required for podocyte injury, since podocytes were
activated in the absence of such an influx. The changeproducing enzyme NAD(P)H oxidase, which is activated
by ATP [41]. Because NO normally counteracts oxida- in podocyte phenotype appeared to be due to decreased
NO-availability, since rats receiving 1% cholesterol plustive stress, when hypercholesterolemia decreases renal
NO-availability, podocyte injury may occur. Podocytes molsidomine had high plasma cholesterol levels but no
podocyte activation.are practically unable to replicate postnatally. Therefore,
any injury that podocytes suffer might lead to areas of As mentioned above, podocyte injury leads to protein-
uria and further renal damage via a cascade of events.“bare” glomerular basement membrane, which are the
starting points for irreversible renal injury [13]. In the At the ultrastructural level increased desmin expression
accompanied by retraction of podocytes results in barepresent study glomerular monocyte influx did not seem
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